Department of Urology, University of Ulm, Ulm, Germany.
Eur Urol. 2012 May;61(5):1039-47. doi: 10.1016/j.eururo.2012.02.028. Epub 2012 Feb 22.
The optimal treatment strategy for muscle-invasive bladder cancer (BCa) remains controversial.
Better define the long-term outcomes of radical cystectomy (RC) alone for BCa and determine the impact of pathologic downstaging after transurethral resection in a large and homogeneous single-center series.
DESIGN, SETTING, AND PARTICIPANTS: A cohort of 1100 patients undergoing RC with pelvic lymph node dissection (PLND) without neoadjuvant therapy for urothelial carcinoma of the bladder between January 1, 1986, and December 2009 was evaluated. Patients with other than metastases to the pelvic lymph nodes were excluded. Median age was 65 yr. Clinical course, pathologic characteristics, and long-term outcomes were evaluated. Follow-up was obtained until December 2009 with a median of 38 mo and a completeness of 96.5%.
RC with PLND; urinary diversion with ileal neobladder whenever possible.
Primary end points were disease-specific survival (DSS), recurrence-free survival (RFS), and overall survival (OS) according to the tumor stage of the RC specimen versus the maximum tumor stage. The log-rank test was used to compare subgroups.
The 30-d (90-d) mortality rate was 3.2% (5.2%). The 10-yr OS, DSS, and RFS rates were 44.3%, 66.8%, and 65.5%, respectively. Based on the tumor stage of the RC specimen, the 10-yr DSS rate was pT0/a/is/1 pN0: 90.5%, pT2a/b pN0: 66.8%, pT3a/b pN0: 59.7%, pT4a/b pN0: 36.6%, and pTall pN+: 16.7%. Downstaging by transurethral resection of the prostate was observed in 382 patients. Patients with maximum tumor stage pT2a/b pN0 had distinctly better 10-yr DSS rates than those with pT2a/b pN0 in the RC specimen: pT2a pN0: 92.2% versus 73.8%; pT2b: 75.0% versus 62.0%. A total of 49% female and 80% male patients received an ileal neobladder.
This contemporary and homogeneous single-center series found acceptable OS, DFS, and RFS for patients undergoing RC. Pathologic downstaging had a significant impact on survival.
肌层浸润性膀胱癌(BCa)的最佳治疗策略仍存在争议。
更好地定义根治性膀胱切除术(RC)单独治疗 BCa 的长期结果,并在大型单一中心系列中确定经尿道前列腺切除术(TURP)后病理降期的影响。
设计、地点和参与者:评估了 1986 年 1 月 1 日至 2009 年 12 月期间接受 RC 联合盆腔淋巴结清扫术(PLND)且无新辅助治疗的膀胱癌尿路上皮癌患者的 1100 例队列。排除了其他部位转移至盆腔淋巴结的患者。中位年龄为 65 岁。评估了临床病程、病理特征和长期结果。中位随访时间为 38 个月(96.5%的完整性),随访至 2009 年 12 月。
RC 联合 PLND;尽可能使用回肠新膀胱进行尿流改道。
主要终点是根据 RC 标本的肿瘤分期与最大肿瘤分期,评估疾病特异性生存(DSS)、无复发生存(RFS)和总生存(OS)。使用对数秩检验比较亚组。
30 天(90 天)死亡率为 3.2%(5.2%)。10 年 OS、DSS 和 RFS 率分别为 44.3%、66.8%和 65.5%。根据 RC 标本的肿瘤分期,10 年 DSS 率为 pT0/a/is/1 pN0:90.5%,pT2a/b pN0:66.8%,pT3a/b pN0:59.7%,pT4a/b pN0:36.6%,pTall pN+:16.7%。382 例患者经 TURP 降期。最大肿瘤分期为 pT2a/b pN0 的患者,其 10 年 DSS 率明显优于 RC 标本中 pT2a/b pN0 的患者:pT2a pN0:92.2% vs 73.8%;pT2b:75.0% vs 62.0%。49%的女性和 80%的男性患者接受了回肠新膀胱。
本研究为接受 RC 的患者提供了可接受的 OS、DFS 和 RFS。病理降期对生存有显著影响。